Alercell is launching a leukemia diagnostic test based on sequencing DNA that will detect up to 51 Genes mutations in Leukemia patients called LENA Q51, which will be available in January 2023.

With Alercell’s LENA Q51, using a qPCR machine, clinicians will be able to identify any gene mutations among 51 different genes in leukemia patients. By doing this, users can make determinations in three hours via computer, eliminating the need for human interpretation. The information gathered will also enable the company to tailor patient treatment.

Additionally, a methylation-based molecular diagnostic test for lung cancer, LENA S1, will be made available by Alercell later in the first quarter of 2023. As an epigenetic regulator of gene expression, DNA methylation enables early diagnosis of lung cancer and very accurate localization of the disease, if present. Alercell Neuroscience will make a formal announcement in early 2023.

Alercell Neuroscience aims to create a nanoparticle neural interface for recording and controlling brain activity. Prof. Gleb Sukhorukov, PhD, Chair in Biopolymers at the School of Engineering and Materials Science, Queen Mary University of London (QMUL), will spearhead these efforts.

Alercell plays a significant role in preventative medicine, particularly in the detection and treatment of cancer. The company’s CEO and the CMO, Alexandre Scheer, MD, are leveraging genetic research to develop novel drugs and testing procedures.

Alercell seeks to provide innovative in-vitro testability for cancer testing while streamlining the process of detecting infectious diseases. Alercell is based in the United States, but also has manufacturing and storage facilities in Europe and Asia, extending its accessibility and reach around the globe.